N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients
- 1 February 2003
- journal article
- research article
- Published by Elsevier in Diabetes & Metabolism
- Vol. 29 (1) , 44-52
- https://doi.org/10.1016/s1262-3636(07)70006-x
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Biochemistry and molecular cell biology of diabetic complicationsNature, 2001
- The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responsesJournal of Clinical Investigation, 2001
- Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing miceJournal of Clinical Investigation, 2001
- Negative consequences of glycationMetabolism, 2000
- Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease.Diabetes Care, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Standardizing the immunological measurement of advanced glycation endproducts using normal human serumJournal of Immunological Methods, 1997
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993
- Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic ComplicationsNew England Journal of Medicine, 1988